利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.032 秒)

    COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    1.
    发明申请
    COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE 有权
    用于治疗自身免疫疾病的BLYS抑制剂和抗CD 20剂的组合

    公开(公告)号：US20090148442A1

    公开(公告)日：2009-06-11

    申请号：US12252955

    申请日：2008-10-16

    申请人： Rafael A. Ponce, JR. ,  Herve Broly ,  Hans Otto Lennart Graffner ,  Sergio Peano

    发明人： Rafael A. Ponce, JR. ,  Herve Broly ,  Hans Otto Lennart Graffner ,  Sergio Peano

    IPC分类号： A61K39/395 ,  A61K38/16 ,  A61P37/02

    CPC分类号： A61K39/3955 ,  A61K38/1709 ,  A61K38/1793 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.

    摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。 一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。 在本发明的方法中，考虑的一些抗CD20药物包括RITUXAN，ocrelizumab，奥美单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的 。 本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。

    Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
    2.
    发明授权
    Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease 有权
    BLyS抑制和抗CD 20药物联合用于治疗自身免疫性疾病

    公开(公告)号：US08956611B2

    公开(公告)日：2015-02-17

    申请号：US12252955

    申请日：2008-10-16

    申请人： Rafael A. Ponce, Jr. ,  Sergio Peano ,  Herve Broly ,  Hans Otto Lennart Graffner

    发明人： Rafael A. Ponce, Jr. ,  Sergio Peano ,  Herve Broly ,  Hans Otto Lennart Graffner

    IPC分类号： A61K39/395 ,  A61K45/06 ,  A61K38/17

    CPC分类号： A61K39/3955 ,  A61K38/1709 ,  A61K38/1793 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.

    摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。 一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。 在本发明的方法中，考虑的一些抗CD20药物包括RITUXAN，（利妥昔单抗），ocrelizumab，奥美珠单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的 。 本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。

    Biological support for cell cultures constituted by plasma proteins coagulated by thrombin, its use in the preparation of keratocyte cultures, their recovery and their transport for therapeutic purposes
    4.
    发明授权
    Biological support for cell cultures constituted by plasma proteins coagulated by thrombin, its use in the preparation of keratocyte cultures, their recovery and their transport for therapeutic purposes 失效
    由凝血酶凝结的血浆蛋白构成的细胞培养物的生物支持，其用于制备角化细胞培养物，其回收及其用于治疗目的的运输

    公开(公告)号：US5474770A

    公开(公告)日：1995-12-12

    申请号：US850260

    申请日：1992-03-12

    申请人： Herve Broly ,  Vincent Ronfard

    发明人： Herve Broly ,  Vincent Ronfard

    IPC分类号： A61L27/60 ,  C12N5/00 ,  C12N5/08 ,  A01N1/02 ,  A61F2/10 ,  C07K14/745

    CPC分类号： A61L27/60 ,  C12N5/0068 ,  C12N2533/56 ,  Y10S623/915

    摘要： The present invention relates to a biological support for cell cultures formed by the coagulated mixture of a concentrate of plasma proteins and thrombin.The protein concentrate is obtained by precipitating fresh plasma with ethanol and contains balanced proportions of fibrinogen, Factor XIII and fibronectin. The thrombin concentration is adjusted to obtain the desired consistency of the support coagulated in the form of a film.The biological support is preferably used for preparing a culture of keratinocytes, recovering them in the form of a reconstituted tissue and transporting same. The reconstituted tissue is thus particularly suitable for use as a graft.

    摘要翻译： 本发明涉及由血浆蛋白和凝血酶浓缩物的凝固混合物形成的细胞培养物的生物支持体。 蛋白浓缩物通过用乙醇沉淀新鲜血浆并含有平衡比例的纤维蛋白原，因子XIII和纤连蛋白获得。 调节凝血酶浓度以获得以膜形式凝结的载体的期望稠度。 生物载体优选用于制备角质形成细胞的培养物，以重组组织的形式回收它们并进行运输。 因此，重组组织特别适合用作移植物。